PD-L1 expression

P2, N=95, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2026 --> Nov 2027

Gut microbiota diversity was associated with the tumor immune microenvironment and nivolumab response in patients with esophageal cancer. Esophagectomy was also associated with alterations in gut microbial composition.

These exploratory data support that pre-BCG microbial features may be related to early response, and post-BCG profiles may reflect durability and survival. Urine immune-microbiome profiling could be a feasible, noninvasive adjunct for monitoring and risk stratification in NMIBC.

Our data suggest that polycystins, PC1 in particular, exert conserved yet context-dependent mechanoregulatory functions in solid tumors. By influencing EMT, migration, tumor progression, and TAZ-mediated mechanotransduction, PC1 emerges as a potential biomarker and mechanotherapeutic target in mechanically responsive cancers.

The findings of this study demonstrated a potential dual role of USP35 in NSCLC, contributing to the targeted therapy of the cancer.

Biomarkers like programmed death ligand-1 (PD-L1) expression, tumor mutational burden and microsatellite stability status have limited roles in HCC and only AFP is used in clinical practice for prediction of treatment benefit in patients recieving ramucirumab...In the European Union, the process involves EMA biomarker qualification procedures and conformity assessment under the In Vitro Diagnostic Regulation. Understanding these scientific, regulatory, and commercial considerations is essential for successfully translating HCC biomarker discoveries into clinical practice.

P2, N=118, Completed, Chipscreen Biosciences, Ltd. | Active, not recruiting --> Completed

P3, N=574, Recruiting, RemeGen Co., Ltd. | Not yet recruiting --> Recruiting

P3, N=750, Recruiting, Amgen | Trial completion date: Jun 2031 --> Jun 2032 | Trial primary completion date: Jun 2026 --> Jun 2027

This study reveals the molecular mechanism by which quercetin directly targets COL3A1 and inhibits the COL3A1/NF-κB/PD-L1 axis, thereby alleviating CD8⁺ T cell exhaustion and enhancing anti-tumor immunity in GC. These findings provide a theoretical basis for the application of Polygonum cuspidatum and quercetin in GC immunotherapy, and suggest that COL3A1 may serve as a potential therapeutic target.

Cadonilimab combined with chemotherapy demonstrated clinically meaningful activity and manageable safety as first-line treatment for advanced or recurrent EC, supporting further investigation, particularly in molecularly defined populations.